SomatoKine mecasermin rinfabate regulatory update

FDA extended the PDUFA date for SomatoKine mecasermin to treat growth hormone insensitivity syndrome (GHIS) by 3 months to Oct. 3 from July 3. The extension will give the agency time to review INSM's ...